|
Scritto da Arthritis News From Medical News Today
|
 Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment. Loss of efficacy was the m ... ...
|
|
|
Scritto da Arthritis News From Medical News Today
|
 Epidemiological data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that pregnancy carried to childbirth (parity) increases the risk of ACPA-negative* rheumatoid arthritis (RA). The increased risk ... ...
|
|
Scritto da Arthritis News From Medical News Today
|
 Two new studies by researchers at Hospital for Special Surgery have shed light on joint replacement outcomes in patients with rheumatoid arthritis (RA). One study overturns the common belief that RA patients have worse outcomes after a total knee rep ... ...
|
|
Scritto da Arthritis News From Medical News Today
|
|
Roche (SIX: RO, ROG; OTCQX: RHHBY) have announced data from two phase III studies using RoActemra in patients with rheumatoid arthritis (RA): the long-term extension (LTE) follow up of the AMBITION study demonstrated long-term efficacy of RoActemra ... ...
|
|
|
Scritto da Arthritis News From Medical News Today
|
 A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis ... ...
|
|
Scritto da Arthritis News From Medical News Today
|
 Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA)... ... ...
|
|
Scritto da Arthritis News From Medical News Today
|
 New data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patient ... ...
|
|
|
<< Inizio < Prec. 1 2 3 4 5 6 7 8 9 10 Succ. > Fine >>
|
|
Pag 1 di 525 |
